News of Note—J&J buys up drug delivery biotech; AstraZeneca out-licenses asset; NASH biotech cancels IPO

Stork ornaments Christmas time Strasbourg France AmaWaterways Editorial use Only Photo by Susan J Young
(Susan J Young)

> Johnson & Johnson has snapped up Taris Biomedical and its drug delivery tech for treatment of bladder diseases including cancer for an undisclosed fee. J&J buys into its leading clinical-stage product, TAR-200, which uses a silicone-based drug delivery device that allows for the continuous release of medication into the bladder.

> Fortress Biotech has spun out a new biotech, known as Baergic Bio, which starts life with a licensing pact with AstraZeneca for AZD7325, an α2/3–subtype-selective GABAA positive allosteric modulator, as well as a deal with Cincinnati Children’s Hospital Medical Center to advance clinical development in certain central nervous system disorders.

> Midstage fatty liver-focused biotech Cirius Therapeutics has cancelled plans for its attempted $86 million initial public offering, with the cash earmarked for MSDC-0602K, a once-daily, oral small molecule for nonalcoholic steatohepatitis with liver scarring. The four-year-old, San Diego-based company was one known as Octeta Therapeutics and has undergone a transformation in recent years with new leadership, a new location and that new name coming in April 2017.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.